We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

7 hedge funds and large institutions have $26K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 7 → 7 (0)

29% less capital invested

Capital invested by funds: $36.8K → $26K (-$10.8K)

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$11.3K – – –
LDB
2
Lee, Danner & Bass
Tennessee
$6K – – –
AW
3
Atlas Wealth
Ohio
$3.06K – – –
LIA
4
LBMC Investment Advisors
Tennessee
$2.49K – – –
ACM
5
Academy Capital Management
Texas
$2.26K – – –
AA
6
Ancora Advisors
Ohio
$865 – – –

PVCT Hedge Fund Activity: Q2 2023 in Review

7 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q2 2023, worth a combined $26K — down 29% from $36.8K a quarter earlier.

Fund positioning in PVCT was balanced in Q2 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 7 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $26K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q2 2023, down 29% quarter-over-quarter.
  • 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q2 2023 and 0 closed out.

Based on aggregated 13F filings for Q2 2023.